Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$3.49 USD
-0.01 (-0.29%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.48 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Werewolf Therapeutics, Inc. [HOWL]
Reports for Purchase
Showing records 21 - 40 ( 45 total )
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the Pack: Initiating with OUTPERFORM and $9 PT
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Ahead of Initial Monotherapy Data For WTX-124 in 4Q23; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progressing a Pipeline of Predators Against Cancer; Reit Buy and $15PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INDUKINE Platform Remains Highly Differentiated, Though Patience is Required; Reit Buy and Lowering Our PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INDUKINEs Take a Step Closer In Transforming Cancer Therapy; Reit Buy and $20PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Green Light for WTX-124 IND Begins Assault on Solid Tumors; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reflections of ASCO ?22 - Part One: Cytokine Modalities Continue to Remain Overlooked
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With a Buy Rating and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q 2021 results; IND Filing for Engineered IL-2 Candidate WTX-124 Set for 2Q 2022; 2nd IND for WTX-330 Set for 3Q 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bempeg Disappoints With Phase 3 Failure; Remain Optimistic on WTX-124 Based on Differentiated Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data From Twin Posters at AACR Supports Clinical Development of Engineered Cytokine Candidates WTX-124 and WTX-330
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Deep Dive on Engineered Cytokines; Using Modern Technology to Teach Old Dogs New Tricks
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Presents Preclinical Data Demonstrating Anti- Tumor Activity of INDUKINES in Hematological Malignancies
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Poster Presentation at ASH Set to Include First Demonstration of INDUKINE Anti-Tumor Activity in Mouse Lymphoma Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Presents Platform Validating Preclinical Data at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Reports 3Q21; IND Filing Plans on Track for 1H 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Paper in Science Immunology Suggests Cytokine Priming is Key to Overcoming Resistance to Immune Checkpoint Blockade
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Engineered Cytokine Wunderkind Werewolf Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Announces Deal With Merck to Test IL-2 INDUKINE - Keytruda Combo in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M